Coronavirus Disease 2019 (COVID-19) and Transplantation: Pharmacotherapeutic Management of Immunosuppression Regimen

References

• Salzberger B, Glück T, Ehrenstein B. Successful containment of COVID-19: the WHO-Report on the COVID-19 outbreak in China. Infection. 2020;48(2):151–153. doi:10.1007/s15010-020-01409-4
   PubMed Web of Science ®Google Scholar
• Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–1069. doi:10.1001/jama.2020.1585
   PubMed Web of Science ®Google Scholar
• WHO. Coronavirus disease (COVID-2019) situation reports. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/. Accessed 29 Mar 2020.
   Google Scholar
• Boeckh M. The challenge of respiratory virus infections in hematopoietic cell transplant recipients. Br J Haematol. 2008;143(4):455–467. doi:10.1111/j.1365-2141.2008.07295.x
   PubMed Web of Science ®Google Scholar
• Garbino J, Crespo S, Aubert JD, et al. A prospective hospital-based study of the clinical impact of non–severe acute respiratory syndrome (Non-SARS)–related human coronavirus infection. Clin Infect Dis. 2006;43(8):1009–1015. doi:10.1086/507898
   PubMed Web of Science ®Google Scholar
• Fernández‐Ruiz M, Andrés A, Loinaz C, et al. COVID‐19 in solid organ transplant recipients: a single‐center case series from Spain. Am J Transplant. 2020. doi:10.1111/ajt.15929
   Web of Science ®Google Scholar
• Angelico R, Trapani S, Manzia TM, Lombardini L, Tisone G, Cardillo M. The COVID‐19 outbreak in Italy: initial implications for organ transplantation programs. Am J Transplant. 2020. doi:10.1111/ajt.15904
   PubMed Web of Science ®Google Scholar
• Vazin A, Fereidooni M. Determining frequency of prescription, administration and transcription errors in internal intensive care unit of Shahid Faghihi Hospital in Shiraz with direct observation approach. Iran J Pharmaceut Sci. 2012;8(3):189–194.
   Google Scholar
• Chan KW, Wong VT, Tang SCW. COVID-19: an update on the epidemiological, clinical, preventive and therapeutic evidence and guidelines of integrative chinese–western medicine for the management of 2019 novel coronavirus disease. Am J Chin Med (Gard City N Y). 2020;1–26.
   Web of Science ®Google Scholar
• Sabrina VL et al. Interim clinical guidance for Patients suspected of/confirmed with COVID-19 in Belgium. 19 March 2020. Available from: https://epedimio.wiv-isp.be/ID/Covi-19/COVID-19_Interim_Guidelines_Treatment/.Accessed March 25, 2020.
   Google Scholar
• Massachusetts General Hospital. Department of Medicine COVID-19 Treatment Guidance. 29 March 2020. Available from: https://www.massgeneral.org/news/coronavirus/coronavirus-media-coverage/.Accessed March, 29 2020.
   Google Scholar
• American Association for the Study of Liver Diseases. Clinical Insights for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic. March 23, 2020. Available from: https://www.aasld.org/sites/default/files/2020-03/AASLD-COVID19-ClinicalInsights-3.23.2020-FINAL-v2.pdf. Accessed March 26, 2020..
   Google Scholar
• Zhu L, Xu X, Ma K, et al. Successful recovery of COVID-19 pneumonia in a renal transplant recipient with long-term immunosuppression. Am J Transplant. n/a(n/a).
   Google Scholar
• Vazin A, Mojtahedzadeh M, Salehifar E, et al. Future drugs for treatment of acute respiratory distress syndrome. Int J Pharmacol. 2005;1:9–16. doi:10.3923/ijp.2005.9.16
   Google Scholar
• Elens L, Langman LJ, Hesselink DA, et al. Pharmacologic treatment of transplant recipients infected with SARS-CoV-2: considerations regarding therapeutic drug monitoring and drug–drug interactions. Ther Drug Monit. 2020;42(3):360–368. doi:10.1097/FTD.0000000000000761
   PubMed Web of Science ®Google Scholar
• Organization WH. Clinical Management of Severe Acute Respiratory Infection When Novel Coronavirus (‎ 2019-Ncov)‎ Infection Is Suspected: Interim Guidance, 28 January 2020. World Health Organization; 2020.
   Google Scholar
• Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020. doi:10.1001/jamainternmed.2020.0994
   Web of Science ®Google Scholar
• Arkas J Internet book of critical care. From EMCrit Project website. Available from: https://emcrit.org/ibcc/COVID19/ Accessed. April 7, 2020.
   Google Scholar
• Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. The Lancet. 2020;395(10223):473–475. doi:10.1016/S0140-6736(20)30317-2
   PubMed Web of Science ®Google Scholar
• Nguyen LS, Vautier M, Allenbach Y, et al. Sirolimus and mTOR inhibitors: a review of side effects and specific management in solid organ transplantation. Drug Safety. 2019;1–13.
   PubMed Web of Science ®Google Scholar
• Liu F, Xu A, Zhang Y, et al. Patients of COVID-19 may benefit from sustained lopinavir-combined regimen and the increase of eosinophil may predict the outcome of COVID-19 progression. Int J Infect Dis. 2020.
   Web of Science ®Google Scholar
• Cao W, Liu X, Bai T, et al. High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with Coronavirus Disease 2019. Paper presented at: Open Forum Infectious Diseases2020.
   Google Scholar
• Bangash MN, Patel J, Parekh D. COVID-19 and the liver: little cause for concern. The Lancet Gastroenterol Hepatol. 2020;5(6):529–530. doi:10.1016/S2468-1253(20)30084-4
   PubMed Web of Science ®Google Scholar
• Xu L, Liu J, Lu M, Yang D, Zheng X. Liver injury during highly pathogenic human coronavirus infections. Liver Int. 2020;40(5):998–1004. doi:10.1111/liv.14435
   PubMed Web of Science ®Google Scholar
• Rismanbaf A, Zarei S. Liver and kidney injuries in COVID-19 and their effects on drug therapy; a letter to editor. Arch Acad Emerg Med. 2020;8(1):e17.
   PubMed Web of Science ®Google Scholar
• Zhang C, Shi L, Wang F-S. Liver injury in COVID-19: management and challenges. The Lancet Gastroenterol Hepatol. 2020;5(5):428–430. doi:10.1016/S2468-1253(20)30057-1
   PubMed Web of Science ®Google Scholar
• Naicker S, Yang C-W, Hwang S-J, Liu B-C, Chen J-H, Jha V. The novel coronavirus 2019 epidemic and kidneys. Kidney Int. 2020;97(5):824–828. doi:10.1016/j.kint.2020.03.001
   PubMed Web of Science ®Google Scholar
• Chinese Medical Association Hepatology drug-induced liver disease study group. Drug-induced liver injury diagnosis and treatment guidelines. J Hepatol. 2015;23(11):810–820. doi:10.3760/cma.j.issn.1007-3418.2015.11.004.
   Google Scholar
• Hu L, Wang W, Zhu Q, Yang L. Novel coronavirus pneumonia related liver injury: etiological analysis and treatment strategy. Zhonghua Gan Zang Bing Za Zhi= Zhonghua Ganzangbing Zazhi= Chinese Journal of Hepatology. 2020;28:E001.
   PubMedGoogle Scholar
• Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. 2020;57:279–283. doi:10.1016/j.jcrc.2020.03.005
   PubMed Web of Science ®Google Scholar
• Sahraei Z, Shabani M, Shokouhi S, Saffaei A. Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or Hydroxychloroquine. Int J Antimicrob Agents. 2020;55(4):105945. doi:10.1016/j.ijantimicag.2020.105945
   PubMed Web of Science ®Google Scholar
• Costedoat-Chalumeau N, Dunogué B, Morel N, Le Guern V, Guettrot-Imbert G. Hydroxychloroquine: a multifaceted treatment in lupus. La Presse Médicale. 2014;43(6):e167–e180. (). doi:10.1016/j.lpm.2014.03.007
   PubMed Web of Science ®Google Scholar
• O’Laughlin JP, Mehta PH, Wong BC. Life threatening severe QTc prolongation in patient with systemic lupus erythematosus due to hydroxychloroquine. Case Rep Cardiol. 2016;2016.
   Google Scholar
• Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis. 2010;69(01):20–28. doi:10.1136/ard.2008.101766
   PubMed Web of Science ®Google Scholar
• Sarzi-Puttini P, D’Ingianna E, Fumagalli M, et al. An open, randomized comparison study of cyclosporine A, cyclosporine A+ methotrexate and cyclosporine A+ hydroxychloroquine in the treatment of early severe rheumatoid arthritis. Rheumatol Int. 2005;25(1):15–22. doi:10.1007/s00296-003-0384-2
   PubMed Web of Science ®Google Scholar
• Ikitimur B, Cosansu K, Karadag B, et al. Long‐term impact of different immunosuppressive drugs on QT and PR intervals in renal transplant patients. Ann Noninvasive Electrocardiol. 2015;20(5):426–432. doi:10.1111/anec.12225
   PubMed Web of Science ®Google Scholar
• Bethel M, Yang FM, Li S, et al. Hydroxychloroquine in patients with systemic lupus erythematosus with end-stage renal disease. J Investigative Med. 2016;64(4):908–910. doi:10.1136/jim-2016-000065
   PubMed Web of Science ®Google Scholar
• Lexi-Drugs. Lexicomp [Internet]. Hudson, OH: Wolters Kluwer Health, Inc. 1978–2020. Chloroquine; [2020 Mar 25] Available from http://online.lexi.com. Accessed June 16, 2020.
   Google Scholar
• Cvetkovic RS, Goa KL. Lopinavir/Ritonavir. Drugs. 2003;63(8):769–802. doi:10.2165/00003495-200363080-00004
   PubMed Web of Science ®Google Scholar
• Yao TT, Qian JD, Zhu WY, Wang Y, Wang GQ. A systematic review of lopinavir therapy for SARS Coronavirus and MERS coronavirus–a possible reference for coronavirus disease‐19 treatment option. J Med Virol. 2020;92(6):556–563. doi:10.1002/jmv.25729
   PubMed Web of Science ®Google Scholar
• Lim J, Jeon S, Shin H-Y, et al. Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR. J Korean Med Sci. 2020;35:6.
   Web of Science ®Google Scholar
• Cao B, Wang Y, Wen D, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382(19):1787–1799. doi:10.1056/NEJMoa2001282
   PubMed Web of Science ®Google Scholar
• Liu J, Shah SK, Basu-Ray I, Garcia-Diaz J, Khalid K, Saeed M. QT prolongation in HIV-positive patients. Indian Heart J. 2019;71(6):434–439. doi:10.1016/j.ihj.2019.11.259
   PubMedGoogle Scholar
• Primeggia J, Timpone JG, Kumar PN. Pharmacologic issues of antiretroviral agents and immunosuppressive regimens in HIV-infected solid organ transplant recipients. Infect Dis Clin. 2013;27(2):473–486. doi:10.1016/j.idc.2013.02.011
   PubMed Web of Science ®Google Scholar
• Van Maarseveen EM, Rogers CC, Trofe-Clark J, Van Zuilen AD, Mudrikova T. Drug–drug interactions between antiretroviral and immunosuppressive agents in HIV-infected patients after solid organ transplantation: a review. AIDS Patient Care STDS. 2012;26(10):568–581. doi:10.1089/apc.2012.0169
   PubMed Web of Science ®Google Scholar
• Bickel M, Anadol E, Vogel M, et al. Daily dosing of tacrolimus in patients treated with HIV-1 therapy containing a ritonavir-boosted protease inhibitor or raltegravir. J Antimicrob Chemother. 2010;65(5):999–1004. doi:10.1093/jac/dkq054
   PubMed Web of Science ®Google Scholar
• Schonder KS, Shullo MA, Okusanya O. Tacrolimus and lopinavir/ritonavir interaction in liver transplantation. Ann Pharmacother. 2003;37(12):1793–1796. doi:10.1345/aph.1D076
   PubMed Web of Science ®Google Scholar
• Badri PS, Parikh A, Coakley EP, et al. Pharmacokinetics of tacrolimus and cyclosporine in liver transplant recipients receiving 3 direct-acting antivirals as treatment for hepatitis C infection. Ther Drug Monit. 2016;38(5):640–645. doi:10.1097/FTD.0000000000000315
   PubMed Web of Science ®Google Scholar
• Barau C, Blouin P, Creput C, Taburet A, Durrbach A, Furlan V. Effect of coadministered HIV‐protease inhibitors on tacrolimus and sirolimus blood concentrations in a kidney transplant recipients. Fundam Clin Pharmacol. 2009;23(4):423–425. doi:10.1111/j.1472-8206.2009.00706.x
   PubMed Web of Science ®Google Scholar
• Jacob S, Nair AB. A review on therapeutic drug monitoring of the mTOR class of immunosuppressants: everolimus and sirolimus. Drugs Ther Perspect. 2017;33(6):290–301. doi:10.1007/s40267-017-0403-0
   Google Scholar
• Meziyerh S, Zwart TC, van Etten RW, et al. Severe COVID‐19 in a renal transplant recipient: a focus on pharmacokinetics. Am J Transplant. 2020. doi:10.1111/ajt.15943
   PubMed Web of Science ®Google Scholar
• Nyström K, Waldenström J, Tang K-W, Lagging M. Ribavirin: pharmacology, multiple modes of action and possible future perspectives. Future Virol. 2019;14(3):153–160. doi:10.2217/fvl-2018-0166
   Web of Science ®Google Scholar
• Foolad F, Aitken SL, Shigle TL, et al. Oral versus aerosolized ribavirin for the treatment of respiratory syncytial virus infections in hematopoietic cell transplant recipients. Clin Infect Dis. 2019;68(10):1641–1649. doi:10.1093/cid/ciy760
   PubMed Web of Science ®Google Scholar
• Arabi YM, Shalhoub S, Mandourah Y, et al. Ribavirin and interferon therapy for critically ill patients with middle east respiratory syndrome: a multicenter observational study. Clin Infect Dis. 2019.
   Web of Science ®Google Scholar
• Ramírez-Olivencia G, Estébanez M, Membrillo FJ, Del Carmen Ybarra M. Use of ribavirin in viruses other than hepatitis C. A review of the evidence. Enfermedades infecciosas y microbiologia clinica (English ed). 2019.
   Web of Science ®Google Scholar
• Kogiso T. Mycophenolate mofetil/ribavirin interaction. Reactions. 2015;1561:125–134.
   Google Scholar
• Brennan B, Wang K, Blotner S, et al. Safety, tolerability, and pharmacokinetics of ribavirin in hepatitis C virus-infected patients with various degrees of renal impairment. Antimicrob Agents Chemother. 2013;57(12):6097–6105. doi:10.1128/AAC.00608-13
   PubMed Web of Science ®Google Scholar
• Tchesnokov EP, Feng JY, Porter DP, Götte M. Mechanism of inhibition of Ebola virus RNA-dependent RNA polymerase by remdesivir. Viruses. 2019;11(4):326. doi:10.3390/v11040326
   PubMed Web of Science ®Google Scholar
• Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020;11(1):1–14. doi:10.1038/s41467-019-13940-6
   PubMed Web of Science ®Google Scholar
• de Wit E, Feldmann F, Cronin J, et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Natl Acad Sci. 2020;117(12):6771–6776. doi:10.1073/pnas.1922083117
   PubMed Web of Science ®Google Scholar
• Li G, De Clercq E. Therapeutic Options for the 2019 Novel Coronavirus (2019-Ncov). Nature Publishing Group; 2020.
   Google Scholar
• National US. ClinicalTrials. Gov. Institutes of Health. Available from: https://clinicaltrials.gov/. Accessed June 16, 2020.
   Google Scholar
• Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19—preliminary report. N Engl J Med. 2020. doi:10.1056/NEJMoa2007764
   Web of Science ®Google Scholar
• Al-Tawfiq JA, Al-Homoud AH, Memish ZA. Remdesivir as a possible therapeutic option for the COVID-19. Travel Med Infect Dis. 2020;34:101615. doi:10.1016/j.tmaid.2020.101615
   PubMed Web of Science ®Google Scholar
• Blaising J, Polyak SJ, Pécheur E-I. Arbidol as a broad-spectrum antiviral: an update. Antiviral Res. 2014;107:84–94. doi:10.1016/j.antiviral.2014.04.006
   PubMed Web of Science ®Google Scholar
• Deng L, Li C, Zeng Q, et al. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: a retrospective cohort study. J Infect. 2020;81(1):e1–e5. doi:10.1016/j.jinf.2020.03.002
   PubMed Web of Science ®Google Scholar
• Li Q, Cheng Q, Zhao Z, et al. Novel Coronavirus Infection and Acute Kidney Injury in Two Renal Transplant Recipients: Case Report. 2020.
   Google Scholar
• Deng P, Zhong D, Yu K, Zhang Y, Wang T, Chen X. Pharmacokinetics, metabolism, and excretion of the antiviral drug arbidol in humans. Antimicrob Agents Chemother. 2013;57(4):1743–1755. doi:10.1128/AAC.02282-12
   PubMed Web of Science ®Google Scholar
• Liu X, Chen X, Liu W, Zhang J, Bi K. Determination of plasma protein binding rate of arbidol. Chin J New Drugs Clin Remedies. 2007;26(2):115.
   Google Scholar
• Jr B S, Mossel EC, Peters C, Garry RF. Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV). Virology. 2004;329(1):11–17. doi:10.1016/j.virol.2004.08.011
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Stepanova M, Henry L, Nader F, Younossi Y, Hunt S. Adherence to treatment of chronic hepatitis C: from interferon containing regimens to interferon and ribavirin free regimens. Medicine. 2016;95(28):28. doi:10.1097/MD.0000000000004151
   Web of Science ®Google Scholar
• Cinatl Jr J Jr, Michaelis M, Scholz M, Doerr HW. Role of interferons in the treatment of severe acute respiratory syndrome. Expert Opin Biol Ther. 2004;4(6):827–836. doi:10.1517/14712598.4.6.827
   PubMed Web of Science ®Google Scholar
• Thiel V, Weber F. Interferon and cytokine responses to SARS-coronavirus infection. Cytokine Growth Factor Rev. 2008;19(2):121–132. doi:10.1016/j.cytogfr.2008.01.001
   PubMed Web of Science ®Google Scholar
• Falzarano D, De Wit E, Rasmussen AL, et al. Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV–infected rhesus macaques. Nat Med. 2013;19(10):1313–1317. doi:10.1038/nm.3362
   PubMed Web of Science ®Google Scholar
• Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 2020;14(1):58–60. doi:10.5582/ddt.2020.01012
   PubMed Web of Science ®Google Scholar
• Cunningham A, Goh H, Koh D. Treatment of COVID-19: old tricks for new challenges. Crit Care. 2020;24.
   PubMed Web of Science ®Google Scholar
• Li L, Han D-K, Lu J. Interferon-α induced severe thrombocytopenia: a case report and review of the literature. World J Gastroenterol. 2010;16(11):1414. doi:10.3748/wjg.v16.i11.1414
   PubMed Web of Science ®Google Scholar
• Fontana RJ, Hayashi P, Bonkovsky HL, et al. Presentation and outcomes with clinically apparent interferon beta hepatotoxicity. Dig Dis Sci. 2013;58(6):1766–1775. doi:10.1007/s10620-012-2553-1
   PubMed Web of Science ®Google Scholar
• Levitsky J, Fiel MI, Norvell JP, et al. Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon. Gastroenterology. 2012;142(5):1132–1139. doi:10.1053/j.gastro.2012.01.030
   PubMed Web of Science ®Google Scholar
• Saab S, Kalmaz D, Gajjar NA, et al. Outcomes of acute rejection after interferon therapy in liver transplant recipients. Liver Transplant. 2004;10(7):859–867. doi:10.1002/lt.20157
   PubMed Web of Science ®Google Scholar
• Selzner N, Guindi M, Renner EL, Berenguer M. Immune-mediated complications of the graft in interferon-treated hepatitis C positive liver transplant recipients. J Hepatol. 2011;55(1):207–217. doi:10.1016/j.jhep.2010.11.012
   PubMed Web of Science ®Google Scholar
• Fraile P, Garcia-Cosmes P, Rosado C, Tabernero J. Interferon-alpha and its deleterious effects on kidney transplant: regarding one case. Nefrología (English Edition). 2009;29(4):366–367.
   PubMed Web of Science ®Google Scholar
• Mehta P, McAuley D, Brown M, Sanchez E, Tattersall R, Manson J. COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet. 2020;395(10229):1033–1034. doi:10.1016/S0140-6736(20)30628-0
   PubMed Web of Science ®Google Scholar
• Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. In: ChinaXiv: 20200300026.2020.
   Google Scholar
• Fontana F, Alfano G, Mori G, et al. Covid‐19 pneumonia in a kidney transplant recipient successfully treated with tocilizumab and hydroxychloroquine. Am J Transplant. 2020. doi:10.1111/ajt.15935
   PubMed Web of Science ®Google Scholar
• Choi J, Aubert O, Vo A, et al. Assessment of Tocilizumab (Anti–Interleukin‐6 Receptor Monoclonal) as a potential treatment for chronic antibody‐mediated rejection and transplant glomerulopathy in HLA‐sensitized renal allograft recipients. Am J Transplant. 2017;17(9):2381–2389. doi:10.1111/ajt.14228
   PubMed Web of Science ®Google Scholar
• Hammami MB, Garibaldi B, Shah P, et al. Clinical Course of COVID‐19 in a liver transplant recipient on hemodialysis and response to tocilizumab therapy: a case report. Am J Transplant. 2020. doi:10.1111/ajt.15985
   PubMed Web of Science ®Google Scholar
• Tocilizumab in COVID-19 Pneumonia (TOCIVID-19) - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/study/NCT04317092?term=tocilizumab&cond=covid&draw=2&rank=1. Accessed March 24, 2020.
   Google Scholar
• Anger F, Wiegering A, Wagner J, et al. Toxic drug-induced liver failure during therapy of rheumatoid arthritis with tocilizumab subcutaneously: a case report. Rheumatology. 2017;56(9):1628–1629. doi:10.1093/rheumatology/kex221
   PubMed Web of Science ®Google Scholar
• Hiura M, Abe S, Tabaru A, et al. Case of severe liver damage after the induction of tocilizumab therapy for rheumatoid vasculitis. Hepatol Res. 2011;41(5):492–496. doi:10.1111/j.1872-034X.2011.00793.x
   PubMed Web of Science ®Google Scholar
• Sonneveld MJ, Murad SD, van der Eijk A, de Man R. Fulminant liver failure due to Hepatitis B reactivation during treatment with tocilizumab. ACG Case Reports Journal. 2019;6(12):e00243. doi:10.14309/crj.0000000000000243
   PubMed Web of Science ®Google Scholar
• Bannwarth B, Richez C. Clinical safety of tocilizumab in rheumatoid arthritis. Expert Opin Drug Saf. 2011;10(1):123–131. doi:10.1517/14740338.2011.537256
   PubMed Web of Science ®Google Scholar
• FitzGerald GA. Misguided drug advice for COVID-19. Science. 2020.
   Web of Science ®Google Scholar
• Day M. Covid-19: Ibuprofen Should Not Be Used for Managing Symptoms, Say Doctors and Scientists. British Medical Journal Publishing Group; 2020.
   Google Scholar
• Qiao W, Wang C, Chen B, et al. Ibuprofen attenuates cardiac fibrosis in streptozotocin-induced diabetic rats. Cardiology. 2015;131(2):97–106. doi:10.1159/000375362
   PubMed Web of Science ®Google Scholar
• Favalli EG, Ingegnoli F, De Lucia O, Cincinelli G, Cimaz R, Caporali R. COVID-19 infection and rheumatoid arthritis: faraway, so close! Autoimmun Rev. 2020;19(5):102523. doi:10.1016/j.autrev.2020.102523
   PubMed Web of Science ®Google Scholar
• Tarus B, Bertrand H, Zedda G, Di Primo C, Quideau S, Slama-Schwok A. Structure-based design of novel naproxen derivatives targeting monomeric nucleoprotein of Influenza A virus. J Biomol Struct Dyn. 2015;33(9):1899–1912. doi:10.1080/07391102.2014.979230
   PubMed Web of Science ®Google Scholar
• Lejal N, Tarus B, Bouguyon E, et al. Structure-based discovery of the novel antiviral properties of naproxen against the nucleoprotein of influenza A virus. Antimicrob Agents Chemother. 2013;57(5):2231–2242. doi:10.1128/AAC.02335-12
   PubMed Web of Science ®Google Scholar
• Zheng W, Fan W, Zhang S, et al. Naproxen exhibits broad anti-influenza virus activity in mice by impeding viral nucleoprotein nuclear export. Cell Rep. 2019;27(6):1875–1885. doi:10.1016/j.celrep.2019.04.053
   PubMed Web of Science ®Google Scholar
• Amici C, Di Coro A, Ciucci A, et al. Indomethacin has a potent antiviral activity against SARS coronavirus. Antivir Ther. 2006;11(8):1021.
   PubMed Web of Science ®Google Scholar
• Adnet F, Slama Schwok A Efficacy of addition of naproxen in the treatment of critically ill patients hospitalized for COVID-19 infection (ENACOVID); 2020. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04325633. [Accessed May 4, 2020
   Google Scholar
• Chiasson JM, Fominaya CE, Gebregziabher M, Taber DJ. Long-term assessment of NSAID prescriptions and potential nephrotoxicity risk in adult kidney transplant recipients. Transplantation. 2019;103(12):2675–2681. doi:10.1097/TP.0000000000002689
   PubMed Web of Science ®Google Scholar
• Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol. 2009;4(2):481–508. doi:10.2215/CJN.04800908
   PubMed Web of Science ®Google Scholar
• Sriuttha P, Sirichanchuen B, Permsuwan U. Hepatotoxicity of nonsteroidal anti-inflammatory drugs: a systematic review of randomized controlled trials. Int J Hepatol. 2018;2018.
   Web of Science ®Google Scholar
• Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: american Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2017;35(28):3240–3261. doi:10.1200/JCO.2017.74.4789
   PubMed Web of Science ®Google Scholar
• Krammes SK, Jacobs T, Clark JM, Lutes RE. Effect of intravenous ondansetron on the QT interval of patients’ electrocardiograms. Pediatr Emerg Care. 2018;34(1):38–41. doi:10.1097/PEC.0000000000000757
   PubMed Web of Science ®Google Scholar
• Warner ME, Naranjo J, Pollard EM, Weingarten TN, Warner MA, Sprung J. Serotonergic medications, herbal supplements, and perioperative serotonin syndrome. Can J Anesth/J canadien d’anesthésie. 2017;64(9):940–946. doi:10.1007/s12630-017-0918-9
   Google Scholar
• Shafiekhani M, Mirjalili M, Vazin A. Psychotropic drug therapy in patients in the intensive care unit–usage, adverse effects, and drug interactions: a review. Ther Clin Risk Manag. 2018;14:1799. doi:10.2147/TCRM.S176079
   PubMed Web of Science ®Google Scholar
• Satish K, Sholapuri D, Niranjane V, Garg S. Efficacy and safety of levocloperastine in the treatment of dry cough: a prospective observational study. J Assoc Phys India. 2018;66:71.
   PubMedGoogle Scholar
• Lai K, Shen H, Zhou X, et al. Clinical practice guidelines for diagnosis and management of cough—Chinese Thoracic Society (CTS) Asthma Consortium. J Thorac Dis. 2018;10(11):6314. doi:10.21037/jtd.2018.09.153
   PubMed Web of Science ®Google Scholar
• Taylor CP, Traynelis SF, Siffert J, Pope LE, Matsumoto RR. Pharmacology of dextromethorphan: relevance to dextromethorphan/quinidine (Nuedexta®) clinical use. Pharmacol Ther. 2016;164:170–182. doi:10.1016/j.pharmthera.2016.04.010
   PubMed Web of Science ®Google Scholar
• Diaz JH. Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19. J Travel Med. 2020;27(3). doi:10.1093/jtm/taaa041
   Web of Science ®Google Scholar
• Kuster GM, Pfister O, Burkard T, et al. SARS-CoV2: should inhibitors of the renin–angiotensin system be withdrawn in patients with COVID-19? Eur Heart J. 2020;41(19):1801–1803. doi:10.1093/eurheartj/ehaa235
   PubMed Web of Science ®Google Scholar
• Fedson DS, Opal SM, Rordam OM. Hiding in plain sight: an approach to treating patients with severe COVID-19 infection. mBio. 2020;11(2):2. doi:10.1128/mBio.00398-20
   Web of Science ®Google Scholar
• Fedson DS, Rordam OM. Treating Ebola patients: a ‘bottom up’approach using generic statins and angiotensin receptor blockers. Int J Infect Dis. 2015;36:80–84. doi:10.1016/j.ijid.2015.04.019
   PubMed Web of Science ®Google Scholar
• Yuan S. Statins may decrease the fatality rate of Middle East respiratory syndrome infection. mBio. 2015;6(4):e01120–01115. doi:10.1128/mBio.01120-15
   PubMed Web of Science ®Google Scholar
• ACC Clinical Bulletin. COVID-19 clinical guidance for the cardiovascular team. March 6, 2020. Available from: https://www.acc.org/latest-in-cardiology/features/~/media/Non-Clinical/Files-PDFs-Excel-MS-Word-etc/2020/02/S20028-ACC-Clinical-Bulletin-Coronavirus.pdf%20%20%20Access/.Accessed 25 March 2020.
   Google Scholar
• Migliozzi DR, Asal NJ. Clinical controversy in transplantation: tacrolimus versus cyclosporine in statin drug interactions. Ann Pharmacother. 2020;54(2):171–177. doi:10.1177/1060028019871891
   PubMed Web of Science ®Google Scholar
• Amundsen R, Christensen H, Zabihyan B, Åsberg A. Cyclosporine A, but not tacrolimus, shows relevant inhibition of organic anion-transporting protein 1B1-mediated transport of atorvastatin. Drug Metabol Disposition. 2010;38(9):1499–1504. doi:10.1124/dmd.110.032268
   PubMed Web of Science ®Google Scholar
• Dashti‐Khavidaki S, Khalili H. Considerations for statin therapy in patients with COVID‐19. Pharmacotherapy. 2020;40(5):484–486. doi:10.1002/phar.2397
   PubMed Web of Science ®Google Scholar
• Gautret P, Lagier J-C, Parola P. et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents;2020. 105949. doi:10.1016/j.ijantimicag.2020.105949
   PubMed Web of Science ®Google Scholar
• Yao T-T, Qian J-D, Zhu W-Y, Wang YWang G-Q. A systematic review of lopinavir therapy for sars coronavirus and mers coronavirus—a possible reference for coronavirus disease‐19 treatment option. J Med Virol. 2020;92(6):556–563. doi:10.1002/jmv.v92.6
   PubMed Web of Science ®Google Scholar
• Chu CM, Cheng VCCHung FN, et al. Role of lopinavir/ritonavir in the treatment of sars: initial virological and clinical findings. Thorax. 2004;59(3):252–256. doi:10.1136/thorax.2003.012658.
   PubMed Web of Science ®Google Scholar
• Al-Homoud AHMemish ZA. Remdesivir as a possible therapeutic option for the covid-19. Travel Med Infect Dis. 2020;34:101615. doi:10.1016/j.tmaid.2020.101615
   PubMed Web of Science ®Google Scholar
• Kennedy GA, Varelias A, Vuckovic SLe Texier L. Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial. Lancet Oncol. 2014;15(13):1451–1459. doi:10.1016/S1470-2045(14)71017-4
   PubMed Web of Science ®Google Scholar
• Shin BH, Everly MJZhang H, et al. Impact of tocilizumab (anti–il-6r) treatment on immunoglobulins and anti-hla antibodies in kidney transplant patients with chronic antibody-mediated rejection. Transplantation. 2020;104(4):856–863. doi:10.1097/TP.0000000000002895.
   PubMed Web of Science ®Google Scholar
• Rico-Mesa JS, White AAnderson AS. Outcomes in patients with covid-19 infection taking acei/arb. Curr Cardiol Rep. 2020;22(5 15): 5 15. doi:10.1007/s11886-020-01291-4
   PubMed Web of Science ®Google Scholar
• Meg J, Xiao GZhang J, et al. Renin-angiotensin system inhibitors improve the clinical outcomes of covid-19 patients with hypertension. Emerging Microbes & Infections. 2020;9(1):757–760. doi:10.1080/22221751.2020.1746200.
   PubMed Web of Science ®Google Scholar
• Shin J-Y, Eberg M, Ernst PFilion KB. Statin potency and the risk of hospitalization for community‐acquired pneumonia. Br J Clin Pharmacol. 2017;83(6):1319–1327. doi:10.1111/bcp.13208
   PubMed Web of Science ®Google Scholar
• Vinogradova Y, Coupland CHippisley-Cox J. Risk of pneumonia in patients taking statins: population-based nested case-control study. Br J Gen Pract. 2011;61(592):e742–748. doi:10.3399/bjgp11X606654
   PubMed Web of Science ®Google Scholar